-
Mashup Score: 5
The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF). Boehringer Ingelheim and Eli Lilly […]
Source: Web Chronicle TodayCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF). Boehringer Ingelheim and Eli Lilly […]
Source: Web Chronicle TodayCategories: Cardiologists, Latest HeadlinesTweet-
@CardioIAN #cardiotwitter #CardioTwitter @MihaiTrofenciuc @cpgale3 @pabeda1 @agtruesdell @SripalBangalore @mirvatalasnag @cardioPCImom https://t.co/26M31bOSAH
-
-
Mashup Score: 0
The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF). Boehringer Ingelheim and Eli Lilly […]
Source: Web Chronicle TodayCategories: Cardiologists, Latest HeadlinesTweet-
SGLT2 inhibitor empagliflozin reduces CV events in prospective trial of HFpEF - with or without diabetes! This is a breakthrough! https://t.co/YSph31Wlhl
-
-
Mashup Score: 21
The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF). Boehringer Ingelheim and Eli Lilly […]
Source: Web Chronicle TodayCategories: Cardiologists, Latest HeadlinesTweet-
🎉🎉🎉🎉🎉 #EMPEROR_PRESERVED significantly ⬇️ the 1st EP: CV-☠️ & HHF in #HFpEF Finally the black beast for the 1st time in the history lost a battle @HFA_President @MarcoMetra @JJheart_doc @JavedButler1 @mvaduganathan @gcfmd @DrMarthaGulati @DBelardoMD https://t.co/k4OEf28MwM https://t.co/5x0bg8KTfK
-
RT @ValleAlfonso: 📂 https://t.co/QrHhuGDBNL